Compare stocks

PYPD vs SHPH

PolyPid Ltd. Ordinary Shares and Shuttle Pharmaceuticals Holdings, Inc. Common Stock

Compare the businesses

PolyPid Ltd. Ordinary Shares

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Open PYPD dashboard ↗

Shuttle Pharmaceuticals Holdings, Inc. Common Stock

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

Open SHPH dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗